Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
What's Your Reaction?
